Copper Radiopharmaceuticals for Molecular Imaging of Alzheimer's Disease

用于阿尔茨海默病分子成像的铜放射性药物

• 批准号: DP0773135
• 负责人: Prof Paul Donnelly
• 金额: $ 16.66万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0773135
• 关键词: Copper; Radiopharmaceuticals; Molecular; Imaging; Alzheimer

The expected outcome of this research is to develop molecular agents to allow non-invasive diagnostic imaging of senile plaques associated with the onset of Alzheimer's disease. This will contribute to a better understanding of the disease, assist in early diagnosis and help assess new intervention strategies. Alzheimer's disease is the most common form of dementia and affects over 160,000 Australians. The imaging agent market is a niche biotechnology industry in which Australia already has an international presence. The proposed research will lead to innovations to ensure Australia remains internationally competitive in this area. This research has potential social and economic benefits for the nation.

这项研究的预期成果是开发分子药物，使非侵入性诊断成像老年斑与阿尔茨海默病的发病。这将有助于更好地了解疾病，协助早期诊断，并帮助评估新的干预战略。阿尔茨海默病是最常见的痴呆症，影响超过16万澳大利亚人。成像剂市场是一个利基生物技术行业，澳大利亚在该行业已经拥有国际影响力。拟议的研究将导致创新，以确保澳大利亚在这一领域保持国际竞争力。这项研究对国家具有潜在的社会和经济效益。